Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) tinted gains of +1.64% (+0.17 points) to US$10.56. The volume of 2.55 Million shares climbed down over an trading activity of 2.89 Million shares. EPS ratio determined by looking at last 12 month figures is -0.29. Over the same time span, the stock marked US$14.97 as its best level and the lowest price reached was US$8.54. The corporation has a market cap of US$1.8 Billion.
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)’s earnings per share has been growing at a 22.34 percent rate over the past 5 year when average revenue increase was noted as 5 percent. The return on equity ratio or ROE stands at 0.2 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0.1 percent and possesses 41.7 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 5 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 13 think it is Hold. Recently, analysts have updated the overall rating to 2.48. 2 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.
Beacon Roofing Supply, Inc. (NASDAQ:BECN) is worth US$2.33 Billion and has recently risen 0.18% to US$33.66. The latest exchange of 0.64 Million shares is below its average trading activity of 850.35 Million shares. The day began at US$33.7 but the price moved to US$33.27 at one point during the trading and finally capitulating to a session high of US$33.84. The stock tapped a 52-week high of US$56.96 while the mean 12-month price target for the shares is US$38.
Currently, the stock carries a price to earnings ratio of 909.73, a price to book ratio of 1.23, and a price to sales ratio of 0.33. For the past 5 years, the company’s revenue has grown 23.4%, while the company’s earnings per share has grown -20.7%. With an institutional ownership near 0%, it carries an earnings per share ratio of 0.04.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 13 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.61.